CureVac (NASDAQ:CVAC) Stock Holdings Lowered by XTX Topco Ltd

XTX Topco Ltd lessened its position in CureVac (NASDAQ:CVAC) by 59.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,812 shares of the company’s stock after selling 18,834 shares during the period. XTX Topco Ltd’s holdings in CureVac were worth $38,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CVAC. Point72 Asset Management L.P. bought a new stake in shares of CureVac during the second quarter valued at approximately $8,237,000. Jane Street Group LLC increased its position in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares during the period. Vanguard Personalized Indexing Management LLC raised its stake in CureVac by 99.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock valued at $147,000 after acquiring an additional 21,999 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock worth $127,000 after acquiring an additional 16,792 shares during the period. Finally, Signaturefd LLC grew its stake in shares of CureVac by 26.9% in the third quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock worth $82,000 after purchasing an additional 5,927 shares in the last quarter. 17.26% of the stock is currently owned by institutional investors.

CureVac Price Performance

Shares of NASDAQ:CVAC opened at $2.87 on Monday. The stock has a market cap of $642.54 million, a price-to-earnings ratio of 5.22, a PEG ratio of 0.24 and a beta of 2.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. CureVac has a 12 month low of $2.21 and a 12 month high of $5.28. The stock’s 50 day moving average price is $2.84 and its 200 day moving average price is $3.18.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.